Drugs / TDENV-LAV F17
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03141138 | Nov 2017 → Oct 2019 | dengue disease | U.S. Army Medical Research and Development Command | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TDENV-LAV F17 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03141138 ↗ |
| Known as | LAV F17 | “TDENV-LAV F17 Dosage: 0.5 mL of the post-transfection LAV F17 vaccine” NCT03141138 ↗ |
| Modality | Vaccine | “2 tetravalent dengue vaccine (TDENV) candidates” NCT03141138 ↗ |
| Route | Subcutaneous | “Mode of administration: subcutaneously” NCT03141138 ↗ |